We shared new data from a post hoc analysis of our Ph 3 Launch-HTN trial during an oral presentation at #ESH2026: in participants with #hypertension and #CKD, lorundrostat significantly reduced #bloodpressure, and among the subset with CKD and baseline albuminuria, UACR.
